The use of multimedia formats for delivering medical communications and education has grown exponentially in the last 10 years, reflecting the changing way we all consume content.
Tumor-agnostic therapy, also known as site-agnostic, genetically defined and biomarker-defined therapy, treats cancer based on its genetic and molecular features without regard to where the cancer started in the body. It has the potential to revolutionalize how we think about treating cancer.
Here at Beehub we enjoy working with both established and emerging biopharmaceutical companies. One question we often hear from start-ups is: at what point should we start medical communications activities for our investigational product?